What's happening about my kmer spectrum? Heterozygous or repeats?
I am doing a denovo genome sequencing and i get the kmer spectrum using clean reads of two paired end libarary data(see attach files). From the plot, i see high sequencing bias and two peaks, but i can not know whether the first peak(highest) is homozygous peak or heterozygous peak, the two situation are quite different. Whether the second peak (2X peak) is from large fragment duplication? or the first peak is heterozygous peak?
-
-
It is difficult to differentiate between zygosity effects and duplications. In part it depends on the type of organism you are sequencing. Plants are notorious for duplications but then it can be easy to breed them to be homozygous. So a bit more information would be appreciated. -
Thank you Westerman. What i am sequencing is a green algae probably diploid but we didnot have direct evidence.Originally posted by westerman View Post
From the kmer spectrum, if the first mean peak is heterozygous peak, then it is so serious. I extracted the longest scaffold and two chloroplast scaffolds from the draft assembly, it shows 1.6%,2.1%,3.1% SNP (i use a simple ciritera: base coverage>=5 and highest nuc > 80%). It is very puzzled (chloroplast SNP>nuclear genome SNP?). One paper sequenced the chloroplast genome but very fragment(the author's explanation is repeats).
Do you know why Dunaliella salina still not public one usable version from JGI? Our algae is near to Dunaliella salina from phylogenetic tree.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment